Medical Device Manufacturers: Hemoperfusion Devices

I. Customer Pain Points

The adsorption column, the core component of blood perfusion devices (used for emergency poisoning treatment and adjunctive therapy in uremia), faces three fundamental challenges: low toxin adsorption capacity, poor blood compatibility, and residual endotoxins, which directly threaten clinical safety and product competitiveness.

The toxin absorption capacity is low, resulting in insufficient clinical efficacy.

Traditional adsorption columns utilize conventional activated carbon (specific surface area: 500–800 m²/g), which exhibit an adsorption capacity of only 50–100 mg/g for uremic toxins (e.g., creatinine, molecular diameter ≈ 0.6 nm) and drug-induced toxins (e.g., acetaminophen, ≈ 0.7 nm). This results in a single-perfusion clearance rate below 40% (while clinical requirements mandate ≥60%). A medical device manufacturer collaborating with Shanxi Xinhua Carbon Technology experienced returns of 10 sets of adsorption columns by the hospital due to insufficient adsorption capacity, resulting in losses exceeding 800,000 yuan.

Poor blood compatibility, leading to complications

Conventional activated carbon exhibits strong hydrophobic properties, readily activates platelets (activation rate>30%) and damages red blood cells (hemolysis rate>5%), leading to complications such as bleeding and anemia in patients (clinical incidence>15%). A blood purification equipment manufacturer collaborating with Shanxi Xinhua Carbon Technology was suspended from procurement by three tertiary hospitals due to hemolytic issues.

Endotoxin residues indicate a high risk of infection

During the production of adsorption columns, activated carbon is prone to carry bacterial endotoxins (concentration: 10–50 EU/mL). Traditional "high-temperature sterilization (121°C)" cannot eliminate free endotoxins, and the products must comply with China YY 0598-2015 "Blood Perfusion Devices" requirement of "endotoxin ≤ 0.5 EU/mL" and the US FDA 21 CFR Part 878 requirement of "endotoxin ≤ 0.25 EU/mL." A medical device manufacturer collaborating with Shanxi Xinhua Carbon Technology once recalled five sets of adsorption columns due to excessive endotoxin levels (1.2 EU/mL), resulting in losses exceeding 400,000 yuan.

II. Application Objectives

The four core objectives of medical device manufacturers using activated carbon are closely aligned with "adsorption capacity, blood compatibility, endotoxin removal, and compliance":

Enhance toxin adsorption capacity to ensure clinical efficacy

Using medical-grade spherical activated carbon (specific surface area 1200–1500 m²/g, particle size 0.3–0.5 mm), the adsorption capacity for creatinine (≈0.6 nm) and paracetamol (≈0.7 nm) was increased to 200–300 mg/g, with a single-perfusion clearance rate of ≥70% (meeting the clinical requirement of ≥60%). After implementation at a medical device manufacturer serving as a partner of Shanxi Xinhua Carbon Technology, the return rate of adsorption columns dropped from 15% to zero.

Improve blood compatibility and reduce complications

By using surface-modified activated carbon (loaded with heparin/PEG) to shield the hydrophobic surface with hydrophilic groups, the platelet activation rate was reduced to <5% and the hemolytic rate to <1% (exceeding the requirement of YY 0598-2015 "hemolytic rate ≤5%"). After the commercial deployment of this blood purification device developed in collaboration with Shanxi Xinhua Carbon Technology, hospital procurement volumes increased from 10 units/month to 30 units/month.

Completely removes endotoxins to ensure safety

By utilizing the pore retention and surface adsorption properties of medical-grade activated carbon (ash content ≤0.3%), the endotoxin removal rate exceeds 99.5% (concentration reduced to <0.1 EU/mL), fully complying with YY 0598-2015 and FDA 21 CFR Part 878 standards. When applied by a medical device manufacturer—a partner of Shanxi Xinhua Carbon Technology—the endotoxin exceedance rate was reduced from 20% to zero.

Strict compliance enables breakthroughs in the international market.

Compliance with global medical device standards:

China YY 0598-2015: Adsorption capacity ≥100 mg/g, endotoxin ≤0.5 EU/mL;

US FDA 21 CFR Part 878: Hemolytic rate ≤5%, endotoxin level ≤0.25 EU/mL;

EU MDD 93/42/EEC: Biocompatibility (cytotoxicity ≤ Grade 1).

III. Application Significance

The application of activated carbon in hemoperfusion devices serves as the core foundation for enterprises to achieve "clinical safety + efficacy assurance + international market approval."

Clinical Safety: Approximately 40% of hemoperfusion complications worldwide are attributed to poor blood compatibility. Activated carbon is one of the few technologies capable of simultaneously enhancing adsorption capacity and improving blood compatibility, thereby directly preventing patient bleeding or anemia (as evidenced by a reduction in complication incidence from 15% to 2% after the commercial deployment of a device used by a partner company of Shanxi Xinhua Carbon Technology).

Efficacy assurance: The adsorption capacity increased from 50–100 mg/g to 200–300 mg/g, and the single-perfusion clearance rate rose from <40% to ≥70%. After implementation by a medical device manufacturer serving as a cooperative client of Shanxi Xinhua Carbon Technology, hospital clinical satisfaction rates improved from 60% to 95%.

International compliance requirements: The EU's Medical Device Directive (MDD) and the U.S. FDA impose stringent regulations on hemoperfusion devices, with the activated carbon process being the only cost-effective solution that meets these standards. Following implementation by a company, exports of adsorption columns to the EU surged from 5 units per month to 25 units per month.

IV. Application History

The application of activated carbon in hemoperfusion devices has been progressively advancing alongside the upgrading of blood purification standards and increasing clinical demands.

1980s: Initial Stage

Asahi Kasei became the first company worldwide to commercialize an activated carbon-based blood perfusion device using spherical activated carbon (specific surface area: 1000 m²/g). Through adsorption and filtration mechanisms, this innovation achieved a phenacetin clearance rate of 60%, marking it as the world's inaugural commercially available activated carbon-based blood perfusion product.

2020s: The Intelligent Phase

China's "14th Five-Year Plan for the Development of Medical Equipment Industry" requires that "the adsorption capacity of hemoperfusion devices be ≥150 mg/g." Activated carbon is integrated with an "online endotoxin monitoring + automatic filling" system to achieve precise quality control (e.g., automatically adjusting the filling amount based on the specific surface area of activated carbon), reducing production errors by 25%.

V. Mechanism of Action

Through a triple mechanism of "high specific surface area adsorption + surface modification compatibility + pore-mediated endotoxin retention," activated carbon addresses the issues of low adsorption capacity, poor blood compatibility, and endotoxin residue in hemoperfusion devices.

1. Adsorption via high specific surface area: "targeted capture" via porous structure

Micro-pores (<2 nm): Account for 70% of the total pore volume (specifically designed for small-molecule toxins), adsorbing urinary toxins (creatinine ≈ 0.6 nm) and drug toxins (paracetamol ≈ 0.7 nm) via van der Waals forces, with an adsorption capacity of 200–300 mg/g (three times that of conventional activated carbon).

Mesopores (2–50 nm): Serving as a "transport channel," they allow medium-sized molecular toxins (e.g., β2-microglobulin ≈3 nm) to diffuse into the micropores, thereby enhancing adsorption efficiency.

Macropores (>50 nm): Functioning as "blood flow channels," they reduce vascular resistance (<100 mmHg) and prevent blood clotting.

2. Surface modification: Enhancement of "blood compatibility" of functional groups

The heparin loaded on the activated carbon surface repels platelets (which carry a negative charge) through negative charge interaction, reducing activation rates to <5%; PEG (polyethylene glycol)-loaded surfaces minimize erythrocyte contact via hydrophobic barriers, resulting in a hemolysis rate of <1% (compared to 5% for conventional activated carbon).

3. Endotoxin removal: pore retention + surface adsorption

The micropores (<2 nm) of activated carbon can retain endotoxins with a molecular weight>1 kDa (size>2 nm), while the oxygen-containing functional groups (-OH, -COOH) on its surface capture free endotoxins via electrostatic adsorption, achieving a removal rate>99.5% (residue <0.1 EU/mL).

VI. Application Methods

Medical device manufacturers employ a combined process of "medical-grade spherical activated carbon preparation + surface modification + endotoxin control," covering all scenarios involving the core components of adsorption columns.

1. Preparation of Medical-grade Spherical Activated Carbon

Application scenario: Hemoperfusion adsorbent (requiring specific surface area of 1200–1500 m²/g, particle size of 0.3–0.5 mm, and ash content ≤ 0.3%).

process sequence ：

Raw material pretreatment: Coconut shell activated carbon → Crushing (<1 mm) → acid washing (5% HCl, removing ash to ≤0.3%).

Spherification: Pickled carbon + binder (PVP) → Granulation (0.3–0.5 mm) → Drying (100°C, 2 hours).

High-temperature activation: KOH activation (KOH/carbon = 3:1) → N₂-protected activation at 900°C → Water washing (to remove K⁺) → Drying (120°C for 2 hours) → Specific surface area of 1200–1500 m²/g, ash content ≤ 0.3%.

2. Surface modification: Heparin/PEG grafting

Application scenario: To improve blood compatibility (requiring platelet activation rate <5% and hemolysis rate <1%).

process sequence ：

Spherical activated carbon → Immersed in heparin solution (10 mg/mL) or PEG solution (5 mg/mL) → Sonicated (30 minutes) → Lyophilized (-50°C, 24 hours) → Surface-loaded with heparin/PEG; platelet activation rate <5%, hemolysis rate <1%.

3. Endotoxin control: Terminal adsorption

Application scenario: Before assembling the adsorption column (endotoxin level must be <0.1 EU/mL).

process sequence ：

Modified activated carbon → loaded into an adsorption column → fed with medical-grade activated carbon particles (0.1–0.3 mm) → static adsorption (30 minutes) → endotoxin removal rate>99.5% (residue <0.1 EU/mL).

VII. Application Process

Taking a blood perfusion device manufacturer (with an annual production capacity of 100,000 units; requiring an adsorption capacity of ≥200 mg/g and endotoxin levels <0.1 EU/mL) as a case study among Shanxi Xinhua Carbon Technology's cooperative clients:

Preparation of medical-grade spherical carbon: coconut shell charcoal → crushing → acid washing (5% HCl) → granulation (0.3–0.5 mm) → KOH activation (900°C, N₂) → water washing → drying → resulting in a specific surface area of 1300 m²/g and ash content of 0.25%.

Surface modification: spherical carbon → immersion in heparin solution (10 mg/mL) → ultrasonication for 30 minutes → freeze-drying → platelet activation rate of 4.5%.

Adsorption column assembly: Modified carbon → Inserted into a polycarbonate housing (volume 200 mL) → Both ends sealed with filter membranes (100 μm) → Fed with medical-grade activated carbon particles (0.2 mm) → Static adsorption for 30 minutes → Endotoxin level <0.08 EU/mL.

Sterilization and Packaging: Ethylene oxide sterilization (37°C, 6 hours) → Sealed packaging → Endotoxin testing (<0.1 EU/mL), adsorption capacity testing (210 mg/g) → Ready for shipment.

Regeneration and Reuse:

Waste adsorption column → High-temperature incineration (850°C, under N₂ protection) → Activated carbon recovery (regeneration rate 80%), with costs only 40% of those for new carbon.

VIII. Application Effects

After modifications by a hemoperfusion device manufacturer, key performance metrics showed significant improvement (based on actual operational data from a collaborating client of Shanxi Xinhua Carbon Technology):

metric	Before modification (ordinary activated carbon)	After modification (medical-grade spherical carbon + heparin modification)	Amplitude Increase	Compliance Status
Adsorption Capacity (mg/g)	80	210	Increased by 162.5%	YY 0598-2015
Platelet activation rate (%):	35	4.5	Decreased by 87.1%	FDA 21 CFR Part 878
hemolysis ratio （%）	6	0.8	Decreased by 86.7%	YY 0598-2015
Endotoxin (EU/mL)	1.2	0.08	Decreased by 93.3%	FDA 21 CFR Part 878
Hospital Return Rate (%)	15	0	Reduce by 100%	—
Monthly Purchase Quantity (sets)	10	30	Increase by 200%	—

IX. Core Advantages

For customized solutions tailored for medical device manufacturers, it offers four irreplaceable advantages:

The product exhibits strong specificity and meets the requirements of blood perfusion therapy.

The developed medical-grade spherical activated carbon (specific surface area: 1200–1500 m²/g; particle size: 0.3–0.5 mm; ash content ≤ 0.3%) is specifically designed to adsorb small-molecule toxins, with an adsorption capacity of 200–300 mg/g (three times that of conventional activated carbon). The heparin/PEG-modified carbon exhibits a platelet activation rate <5% and a hemolysis rate <1%. After implementation by a medical device manufacturer serving as a partner of Shanxi Xinhua Carbon Technology, the return rate of adsorption columns decreased from 15% to zero.

Good blood compatibility, reducing complications

The surface-modified activated carbon utilizes a mechanism of "negative charge repulsion + hydrophilic barrier," resulting in a platelet activation rate <5% and a hemolysis rate <1% (exceeding the requirement of YY 0598-2015, which stipulates "hemolysis rate ≤5%"). Following the commercial deployment of this blood purification device by a partner company of Shanxi Xinhua Carbon Technology, hospital procurement volumes increased from 10 units per month to 30 units per month.

Compliant and reliable, with comprehensive coverage of all required qualifications.

The product has obtained certifications under YY 0598-2015 "Hemoperfusion Devices," FDA 21 CFR Part 878 (Hemoperfusion Equipment), and EU MDD 93/42/EEC (Medical Device Directive), fully complying with global medical device standards.

Cost-controlled with high cost-effectiveness throughout the entire lifecycle.

Medical-grade spherical carbon: Can be regenerated up to three times (with regeneration costs accounting for 40% of new carbon production), requiring an initial investment of only 1.5–2 million yuan per 100,000 units with annual production capacity.

Surface modification process: Operating cost of 5–10 yuan per set (half that of the traditional method). A manufacturer collaborating with Shanxi Xinhua Carbon Technology has reduced its annual production cost by 50% (from 1 million yuan to 500,000 yuan).

X. Cost Analysis

Taking an annual production capacity of 100,000 hemoperfusion sets as an example, the cost comparison between the activated carbon process and the traditional process is as follows:

project	Medical-grade spherical carbon + modified manufacturing process	Conventional activated carbon + high-temperature sterilization process
Initial Investment (Ten Thousand Yuan)	180-250	100-150
Operating Cost (RMB per Set)	15-20	30-40
Maintenance Cost (RMB 10,000/year)	20-30	50-80
Total Life Cycle Cost (RMB per set)	30-40	60-80
Return Loss (Ten Thousand Yuan per Year)	0	80

XI. Why Choose Us?

Performance endorsement: Activated carbon, renowned for its "high adsorption capacity and excellent blood compatibility," has received unanimous acclaim. A medical device manufacturer—a partner of Shanxi Xinhua Carbon Technology—found that after modifying our medical-grade spherical carbon with heparin, the adsorption capacity increased from 80 mg/g to 210 mg/g, while the hospital return rate dropped from 15% to zero.

Technical Strength: The pore structure has been optimized for blood perfusion toxins (creatinine ≈0.6 nm, acetaminophen ≈0.7 nm), with the development of "spherical carbon with a specific surface area of 1300 m²/g" and "heparin/PEG-modified carbon." The platelet activation rate is <5%, addressing the critical issue of poor blood compatibility associated with traditional processes.

Global Services: We operate production facilities in Shanxi, Ningxia, and Fujian (with an annual capacity of 45,000 tons), offering a "customized production + localized delivery" solution. For international clients, we provide end-to-end services covering activated carbon selection, adsorption column design, and regulatory compliance certification (FDA/MDD), ensuring prompt response within 72 hours.​​​​​​​